Trevi Therapeutics (TRVI) Expected to Announce Earnings on Tuesday

Trevi Therapeutics (NASDAQ:TRVI) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 17, 2026 at 4:30 PM ET.

Trevi Therapeutics Stock Performance

Trevi Therapeutics stock opened at $11.01 on Monday. The company has a 50 day moving average price of $11.17 and a 200-day moving average price of $10.87. Trevi Therapeutics has a fifty-two week low of $4.85 and a fifty-two week high of $14.39. The company has a market capitalization of $1.41 billion, a PE ratio of -29.76 and a beta of 0.94.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TRVI shares. B. Riley Financial raised Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, November 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, January 21st. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Monday, March 9th. Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a report on Monday, March 9th. Finally, Stifel Nicolaus increased their target price on shares of Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $21.10.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TRVI. AQR Capital Management LLC raised its position in shares of Trevi Therapeutics by 20.4% in the 1st quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock worth $174,000 after acquiring an additional 4,688 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Trevi Therapeutics by 31.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company’s stock valued at $278,000 after purchasing an additional 10,445 shares in the last quarter. Millennium Management LLC grew its stake in Trevi Therapeutics by 356.3% in the first quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock valued at $5,178,000 after purchasing an additional 642,830 shares during the last quarter. Strs Ohio purchased a new position in Trevi Therapeutics in the first quarter valued at about $52,000. Finally, Creative Planning raised its holdings in Trevi Therapeutics by 17.5% in the second quarter. Creative Planning now owns 20,247 shares of the company’s stock worth $111,000 after purchasing an additional 3,016 shares in the last quarter. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.